AGA's POWER 2.0 brings obesity treatment into routine GI care

The American Gastroenterological Association published POWER 2.0 on June 17, 2026, updating its practice guide for obesity and weight management in gastroenterology and hepatology. The central message is that obesity care belongs inside these specialties rather than being treated as a separate issue or left to a single type of clinician.

The guide describes a multidisciplinary process that can draw on nutrition and other lifestyle support, obesity medications and procedures. For GI specialists, that can include combining newer medicines with endoscopic treatment while coordinating care with the rest of a patient's clinical team. The AGA calls POWER 2.0 a live document, which allows it to change as evidence and treatment options develop.

This is a meaningful shift in how the treatment conversation is framed. Medication, endoscopy and bariatric surgery are not automatically rival camps. They may be considered at different points, and more than one approach may be used over time when the patient's condition, response and preferences support it.

The guidance promotes a stepped, personalized model that integrates lifestyle care, GLP-1 medications, endoscopic therapies, and bariatric surgery as escalating options rather than competing channels.

Obesity care becomes part of routine GI practice

Patients may hear more GI specialists discuss obesity directly, including how excess weight relates to liver and digestive disease. The guide gives those practices a framework for assessing patients, offering treatment and coordinating referrals instead of addressing only one obesity-related complication at a time.

It also supports a more flexible treatment path. Someone may start with one option, change course after an inadequate response or use medical and procedural care together. The appropriate sequence still depends on the person's health, goals, prior treatment and access to care.

Specialty societies keep converging on the same architecture: start with lifestyle and medications for many patients, escalate to endoscopic or surgical intervention when results are inadequate, and combine modalities when appropriate. For readers deciding between "the shot" and "the surgery," the gastroenterologists' answer is increasingly: it depends on where you are on the ladder, not either/or.

The framework does not determine individual treatment

POWER 2.0 is professional guidance, not an insurance coverage decision or a rule that every patient must move through the same steps. It does not make every gastroenterology practice a bariatric program, and it does not establish that combination treatment is better for every person.

The guide also does not replace individualized evaluation for a medicine, endoscopic procedure or operation. Each option has its own eligibility criteria, expected benefits, adverse effects and follow-up needs.

A professional framework changes no one's insurance coverage and binds no plan. It is not a claim that escalation is required, nor that combination therapy is superior for everyone; individual candidacy still drives sequencing.